PJS 539
Alternative Names: PJS-539Latest Information Update: 28 Feb 2024
At a glance
- Originator University of California, San Diego
- Developer CoviCept Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Dengue; Zika virus infection
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (PO, Liquid)
- 04 Mar 2022 Covicept Therapeutics completes a phase-II clinical trial in COVID-2019 infections (In adults) in Brazil (PO) (NCT05008393)
- 25 Sep 2021 Phase-II clinical trials in COVID-2019 infections (In adults) in Brazil (PO) (NCT05008393)